What was Johnson & Johnson's revenue in Q2 2026?

JNJ reported revenue of $22.8 billion in Q2 2026, up 4.5% year-over-year.

Why did JNJ stock fall despite beating estimates?

The stock declined due to slower-than-expected MedTech growth of just 2.8%, which disappointed investors.

What is JNJ's raised guidance for 2026?

JNJ now expects 2026 revenue of $89.5B to $90.5B and EPS of $11.20 to $11.30.

How did JNJ's MedTech unit perform?

MedTech generated $7.5 billion in Q2 revenue, growing only 2.8%, below expectations.

Johnson & Johnson Beats Q2 Estimates, Raises 2026 Guidance

Johnson & Johnson (JNJ) beat analyst expectations in Q2 2026, reporting revenue of $22.8 billion and EPS of $2.80. The company raised its full-year guidance, but shares declined due to slower-than-expected MedTech growth.

Johnson & Johnson (NYSE: JNJ) reported strong financial results for the second quarter of 2026, surpassing analyst estimates. Revenue came in at $22.8 billion, up 4.5% year-over-year, while earnings per share (EPS) reached $2.80, a 6.1% increase. Despite the beat, JNJ shares edged lower in after-hours trading.

Key Financial Results

Metric	Q2 2026	YoY Change
Revenue	$22.8B	+4.5%
EPS	$2.80	+6.1%
MedTech Revenue	$7.5B	+2.8%
Pharmaceutical Revenue	$15.3B	+5.4%

Highlights from the Report

The company attributed strong growth to its pharmaceutical segment, particularly Stelara and Darzalex. However, the MedTech unit grew only 2.8%, missing expectations and raising concerns among investors.

Guidance Update

JNJ raised its full-year 2026 guidance, now expecting revenue between $89.5B and $90.5B, and EPS between $11.20 and $11.30. Previous guidance was $88-89B and $10.95-$11.05, respectively.

Stock Reaction

Despite the earnings beat and raised guidance, JNJ shares fell approximately 0.8% after the announcement. Analysts attribute the decline to disappointing MedTech growth, a key driver for future expansion.

What This Means for Investors

JNJ remains a fundamentally strong company, but the MedTech slowdown warrants attention. Investors may prefer to wait for improvement in that segment before increasing positions.